Fujun Wang

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial

Dicer Inhibits Hepatocellular Carcinoma by Inhibiting the Interleukin 6 Pathway

miR-146a suppresses the expression of vascular endothelial growth factor and inflammatory responses in diabetic retinopathy

N-type calcium channel and renal injury

Dicer induced reactive oxygen species inhibit hepatocellular carcinoma through interacting with cytochrome c oxidase

Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis

Silencing of FOS-like antigen 1 represses restenosis <i>via</i> the ERK/AP-1 pathway in type 2 diabetic mice

Effect of umbilical cord blood stem cell transplantation on restenosis after endovascular interventional therapy for diabetic hindlimb vascular disease

Right costophrenic angle abscess due to <i>Salmonella</i> Dublin infection in combination with type 2 diabetes mellitus

LncRNA MALAT1 induces the dysfunction of β cells via reducing the histone acetylation of the PDX-1 promoter in type 1 diabetes

Five‐year follow‐up observation of interventional therapy for lower extremity vascular disease in type 2 diabetes and analysis of risk factors for restenosis

HUCMNCs protect vascular endothelium and prevent ISR after endovascular interventional therapy for vascular diseases in T2DM rabbits

Effects of Endovascular Interventions on vWF and Fb Levels in Type 2 Diabetic Patients with Peripheral Artery Disease

CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer

Effects of percutaneous lower-extremity arterial interventions on endothelial function and inflammation response in patients with both type 2 diabetes and lower-extremity peripheral arterial disease.